FIELD: pharmaceutics.
SUBSTANCE: invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof, wherein the prodrug has formula (IIf'),
where the unlabelled dotted line shows the attachment to the nitrogen atom provided by the lysine side chain at position 26 of the CNP fragment of the sequence SEQ ID NO: 24 by forming an amide bond; and the dotted line marked with an asterisk denotes attachment to -Z, having a structure of formula (h-i),
where each -Zc is
each c1 is independently an integer in range from 200 to 250. Also disclosed is a pharmaceutical composition containing at least one CNP prodrug or a pharmaceutically acceptable salt thereof, and use of the CNP prodrug for treating achondroplasia.
EFFECT: treatment of achondroplasia.
12 cl, 1 dwg, 2 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
| PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS | 2017 |
|
RU2766959C2 |
| DOSAGE MODE OF PTH COMPOUND OF CONTROLLED RELEASE | 2017 |
|
RU2777357C2 |
| LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES | 2020 |
|
RU2817015C2 |
| USE OF OPTIONS OF NATRIURETIC PEPTIDE OF TYPE C FOR TREATMENT OF OSTEOARTHRITIS | 2016 |
|
RU2759679C2 |
| ANTIBODY-DRUG CONJUGATES INCLUDING ANTIBODY AGAINST HUMAN DLK1 AND THEIR USE | 2020 |
|
RU2801630C2 |
| ANTIBODY-DRUG CONJUGATE, INTERMEDIATE FOR ITS PRODUCTION, METHOD OF ITS PRODUCTION AND ITS USE | 2020 |
|
RU2800137C1 |
| IMPROVED FACTOR IX FUNCTION PROTEIN AND ITS CONJUGATE AND THEIR USE | 2020 |
|
RU2794350C1 |
| PRODRUG COMPOSITIONS BASED ON CROSS-LINKED HYALURONIC ACID HYDROGEL AND METHODS OF THEIR PRODUCTION | 2018 |
|
RU2812787C2 |
| 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USE THEREOF IN TREATING DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 OF IKAROS (IKZF2) FAMILY | 2019 |
|
RU2815714C2 |
